Table 7.
Base case results: cost-effectiveness
| FDC tablet solifenacin 6 mg + TOCAS | Tolterodine + tamsulosin | |
|---|---|---|
| Total costs* (£) | 860 | 959 |
| Difference | – | −99 |
| QALYs* | 0.840 | 0.836 |
| Difference | – | 0.002 |
| ICER*‡ | – | Dominates (−£40,469) |
*Per patient at 1 year.
‡FDC tablet solifenacin 6 mg + TOCAS versus tolterodine + tamsulosin.
FDC, fixed-dose combination; ICER, incremental cost effectiveness ratio; QALY, quality of life adjusted years; TOCAS, oral controlled absorption system (OCAS™) formulation of tamsulosin.